年別の研究成果
年別の研究成果
検索結果
-
2023
ASO Author Reflections: Novel Evidence on Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer with Arterial Involvement
Ikenaga, N., Miyasaka, Y., Ohtsuka, T. & Nakamura, M., 1月 2023, In: Annals of Surgical Oncology. 30, 1, p. 203-204 2 p.研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読
-
2022
Erratum to “ERAP2 is a novel target involved in autophagy and activation of pancreatic stellate cells via UPR signaling pathway” [Pancreatology 22 (1) (2022 Jan) 9-19] (Pancreatology (2022) 22(1) (9–19), (S1424390321005767), (10.1016/j.pan.2021.09.012))
Guan, W., Nakata, K., Sagara, A., Iwamoto, C., Endo, S., Matsuda, R., Matsumoto, S., Ikenaga, N., Shindo, K., Moriyama, T., Onishi, H., Ohuchida, K., Oda, Y. & Nakamura, M., 11月 2022, In: Pancreatology. 22, 7, p. 1059 1 p.研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読
Open Access -
2021
Erratum: LAMA4 upregulation is associated with high liver metastasis potential and poor survival outcome of pancreatic cancer: Erratum (Theranostics (2020) 10:22 (10274-10289) DOI: 10.7150/thno.47001)
Zheng, B., Qu, J., Ohuchida, K., Feng, H., Chong, S. J. F., Yan, Z., Piao, Y., Liu, P., Sheng, N., Eguchi, D., Ohtsuka, T., Mizumoto, K., Liu, Z., Pervaiz, S., Gong, P. & Nakamura, M., 2021, In: Theranostics. 11, 20, p. 10171-10172 2 p.研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読
Open Access3 被引用数 (Scopus) -
2019
ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes
Miyasaka, Y. & Nakamura, M., 12月 1 2019, In: Annals of Surgical Oncology. 26, p. 739-740 2 p.研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読
2 被引用数 (Scopus)